The role of wild type RAS isoforms in cancer

Seminars in Cell and Developmental Biology

Volumn 58, Issue , 2016, Pages 60-69

  Zhou, Bingying ^a   Der, Channing J ^a   Cox, Adrienne D ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Isoform; Mutant; RAS; RASGAP; Wild type

Indexed keywords

DUAL SPECIFICITY PHOSPHATASE; GUANOSINE TRIPHOSPHATASE; RAS PROTEIN; SPROUTY PROTEIN; TUMOR PROMOTER; TUMOR SUPPRESSOR PROTEIN; ISOPROTEIN;

ALLELE; CHEMICAL CARCINOGENESIS; FEEDBACK SYSTEM; GENE FUSION; NONHUMAN; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; AMINO ACID SEQUENCE; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; GENETICS; HUMAN; METABOLISM; MUTATION; NEOPLASM;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; PROTEIN ISOFORMS; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84991087049     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2016.07.012     Document Type: Review

References (98)

1. [1] Wennerberg, K., Rossman, K.L., Der, C.J., The Ras superfamily at a glance. J. Cell Sci. 118:Pt 5 (2005), 843–846.
2. [2] Cox, A.D., Der, C.J., Ras history: the saga continues. Small GTPases 1:1 (2010), 2–27.
3. [3] Karnoub, A.E., Weinberg, R.A., Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 9:7 (2008), 517–531.
4. [4] Cox, A.D., Fesik, S.W., Kimmelman, A.C., Luo, J., Der, C.J., Drugging the undruggable RAS: mission possible?. Nat. Rev. Drug Discov. 13:11 (2014), 828–851.
5. [5] Pylayeva-Gupta, Y., Grabocka, E., Bar-Sagi, D., RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11:11 (2011), 761–774.
6. [6] Vigil, D., Cherfils, J., Rossman, K.L., Der, C.J., Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?. Nat. Rev. Cancer 10:12 (2010), 842–857.
7. [7] Maertens, O., Cichowski, K., An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer. Adv. Biol. Regul. 55 (2014), 1–14.
8. [8] Tsai, F.D., Lopes, M.S., Zhou, M., Court, H., Ponce, O., Fiordalisi, J.J., Gierut, J.J., Cox, A.D., Haigis, K.M., Philips, M.R., K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif. Proc. Natl. Acad. Sci. U. S. A. 112:3 (2015), 779–784.
9. [9] Cox, A.D., Der, C.J., Philips, M.R., Targeting RAS membrane association: back to the future for anti-RAS drug discovery?. Clin. Cancer Res. 21:8 (2015), 1819–1827.
10. [10] Prior, I.A., Hancock, J.F., Ras trafficking, localization and compartmentalized signalling. Semin. Cell Dev. Biol. 23:2 (2012), 145–153.
11. [11] Omerovic, J., Prior, I.A., Compartmentalized signalling: ras proteins and signalling nanoclusters. FEBS J. 276:7 (2009), 1817–1825.
12. [12] Plowman, S.J., Muncke, C., Parton, R.G., Hancock, J.F., K-ras, H-ras, plasma, inner, membrane raft proteins operate in nanoclusters with differential dependence on the actin cytoskeleton. Proc. Natl. Acad. Sci. U. S. A. 102:43 (2005), 15500–15505.
13. [13] Cox, A.D., Der, C.J., The dark side of Ras: regulation of apoptosis. Oncogene 22:56 (2003), 8999–9006.
14. [14] Hamilton, M., Wolfman, A., Ha-ras and N-ras regulate MAPK activity by distinct mechanisms in vivo. Oncogene 16:11 (1998), 1417–1428.
15. [15] Voice, J.K., Klemke, R.L., Le, A., Jackson, J.H., Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility. J. Biol. Chem. 274:24 (1999), 17164–17170.
16. [16] Yan, J., Roy, S., Apolloni, A., Lane, A., Hancock, J.F., Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J. Biol. Chem. 273:37 (1998), 24052–24056.
17. [17] Castellano, E., Santos, E., Functional specificity of ras isoforms: so similar but so different. Genes Cancer 2:3 (2011), 216–231.
18. [18] Fotiadou, P.P., Takahashi, C., Rajabi, H.N., Ewen, M.E., Wild-type NRas and KRas perform distinct functions during transformation. Mol. Cell. Biol. 27:19 (2007), 6742–6755.
19. [19] Haigis, K.M., Kendall, K.R., Wang, Y., Cheung, A., Haigis, M.C., Glickman, J.N., Niwa-Kawakita, M., Sweet-Cordero, A., Sebolt-Leopold, J., Shannon, K.M., Settleman, J., Giovannini, M., Jacks, T., Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat. Genet. 40:5 (2008), 600–608.
20. [20] Newlaczyl, A.U., Hood, F.E., Coulson, J.M., Prior, I.A., Decoding RAS isoform and codon-specific signalling. Biochem. Soc. Trans. 42:4 (2014), 742–746.
21. [21] Parikh, C., Subrahmanyam, R., Ren, R., Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice. Cancer Res. 67:15 (2007), 7139–7146.
22. [22] Quinlan, M.P., Settleman, J., Isoform-specific ras functions in development and cancer. Future Oncol. 5:1 (2009), 105–116.
23. [23] Whitwam, T., Vanbrocklin, M.W., Russo, M.E., Haak, P.T., Bilgili, D., Resau, J.H., Koo, H.M., Holmen, S.L., Differential oncogenic potential of activated RAS isoforms in melanocytes. Oncogene 26:31 (2007), 4563–4570.
24. [24] Johnson, L., Greenbaum, D., Cichowski, K., Mercer, K., Murphy, E., Schmitt, E., Bronson, R.T., Umanoff, H., Edelmann, W., Kucherlapati, R., Jacks, T., K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes. Dev. 11:19 (1997), 2468–2481.
25. [25] Koera, K., Nakamura, K., Nakao, K., Miyoshi, J., Toyoshima, K., Hatta, T., Otani, H., Aiba, A., Katsuki, M., K-ras is essential for the development of the mouse embryo. Oncogene 15:10 (1997), 1151–1159.
26. [26] Potenza, N., Vecchione, C., Notte, A., De Rienzo, A., Rosica, A., Bauer, L., Affuso, A., De Felice, M., Russo, T., Poulet, R., Cifelli, G., De Vita, G., Lembo, G., Di Lauro, R., Replacement of K-Ras with H-Ras supports normal embryonic development despite inducing cardiovascular pathology in adult mice. EMBO Rep. 6:5 (2005), 432–437.
27. [27] Umanoff, H., Edelmann, W., Pellicer, A., Kucherlapati, R., The murine N-ras gene is not essential for growth and development. Proc. Natl. Acad. Sci. U. S. A. 92:5 (1995), 1709–1713.
28. [28] Perez de Castro, I., Diaz, R., Malumbres, M., Hernandez, M.I., Jagirdar, J., Jimenez, M., Ahn, D., Pellicer, A., Mice deficient for N-ras: impaired antiviral immune response and T-cell function. Cancer Res. 63:7 (2003), 1615–1622.
29. [29] Esteban, L.M., Vicario-Abejon, C., Fernandez-Salguero, P., Fernandez-Medarde, A., Swaminathan, N., Yienger, K., Lopez, E., Malumbres, M., McKay, R., Ward, J.M., Pellicer, A., Santos, E., Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol. Cell. Biol. 21:5 (2001), 1444–1452.
30. [30] Ise, K., Nakamura, K., Nakao, K., Shimizu, S., Harada, H., Ichise, T., Miyoshi, J., Gondo, Y., Ishikawa, T., Aiba, A., Katsuki, M., Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis. Oncogene 19:26 (2000), 2951–2956.
31. [31] Hobbs, G.A., Der, C.J., Rossman, K.L., RAS isoforms and mutations in cancer at a glance. J. Cell Sci. 129:7 (2016), 1287–1292.
32. [32] Westcott, P.M., Halliwill, K.D., To, M.D., Rashid, M., Rust, A.G., Keane, T.M., Delrosario, R., Jen, K.Y., Gurley, K.E., Kemp, C.J., Fredlund, E., Quigley, D.A., Adams, D.J., Balmain, A., The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 517:7535 (2015), 489–492.
33. [33] Pershing, N.L., Lampson, B.L., Belsky, J.A., Kaltenbrun, E., MacAlpine, D.M., Counter, C.M., Rare codons capacitate Kras-driven de novo tumorigenesis. J. Clin. Invest. 125:1 (2015), 222–233.
34. [34] Courtois-Cox, S., Genther Williams, S.M., Reczek, E.E., Johnson, B.W., McGillicuddy, L.T., Johannessen, C.M., Hollstein, P.E., MacCollin, M., Cichowski, K., A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10:6 (2006), 459–472.
35. [35] Dimauro, T., David, G., Ras-induced senescence and its physiological relevance in cancer. Curr. Cancer Drug Targets 10:8 (2010), 869–876.
36. [36] Guerra, C., Mijimolle, N., Dhawahir, A., Dubus, P., Barradas, M., Serrano, M., Campuzano, V., Barbacid, M., Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4:2 (2003), 111–120.
37. [37] Spandidos, D.A., Sourvinos, G., Tsatsanis, C., Zafiropoulos, A., Normal ras genes: their onco-suppressor and pro-apoptotic functions (review). Int. J. Oncol. 21:2 (2002), 237–241.
38. [38] To, M.D., Perez-Losada, J., Mao, J.H., Hsu, J., Jacks, T., Balmain, A., A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. Nat. Genet. 38:8 (2006), 926–930.
39. [39] Lampson, B.L., Pershing, N.L., Prinz, J.A., Lacsina, J.R., Marzluff, W.F., Nicchitta, C.V., MacAlpine, D.M., Counter, C.M., Rare codons regulate KRas oncogenesis. Curr. Biol.: CB 23:1 (2013), 70–75.
40. [40] Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., Antipin, Y., Reva, B., Goldberg, A.P., Sander, C., Schultz, N., The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:5 (2012), 401–404.
41. [41] Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., Cerami, E., Sander, C., Schultz, N., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal., 6(269), 2013, pl1.
42. [42] Spandidos, A., Wilkie, N.M., The normal human H-ras1 gene can act as an onco-suppressor. Br. J. Cancer 9:Supplement (1988), 67–71.
43. [43] Spandidos, D.A., Frame, M., Wilkie, N.M., Expression of the normal H-ras1 gene can suppress the transformed and tumorigenic phenotypes induced by mutant ras genes. Anticancer Res. 10:6 (1990), 1543–1554.
44. [44] Bremner, R., Balmain, A., Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell 61:3 (1990), 407–417.
45. [45] Bremner, R., Kemp, C.J., Balmain, A., Induction of different genetic changes by different classes of chemical carcinogens during progression of mouse skin tumors. Mol. Carcinog. 11:2 (1994), 90–97.
46. [46] Guerrero, I., Villasante, A., Corces, V., Pellicer, A., Loss of the normal N-ras allele in a mouse thymic lymphoma induced by a chemical carcinogen. Proc. Natl. Acad. Sci. U. S. A. 82:23 (1985), 7810–7814.
47. [47] Zhang, Z., Wang, Y., Vikis, H.G., Johnson, L., Liu, G., Li, J., Anderson, M.W., Sills, R.C., Hong, H.L., Devereux, T.R., Jacks, T., Guan, K.L., You, M., Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat. Genet. 29:1 (2001), 25–33.
48. [48] Diaz, R., Ahn, D., Lopez-Barcons, L., Malumbres, M., Perez de Castro, I., Lue, J., Ferrer-Miralles, N., Mangues, R., Tsong, J., Garcia, R., Perez-Soler, R., Pellicer, A., The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene. Cancer Res. 62:15 (2002), 4514–4518.
49. [49] To, M.D., Rosario, R.D., Westcott, P.M., Banta, K.L., Balmain, A., Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis. Oncogene 32:34 (2013), 4028–4033.
50. [50] To, M.D., Wong, C.E., Karnezis, A.N., Del Rosario, R., Di Lauro, R., Balmain, A., Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat. Genet. 40:10 (2008), 1240–1244.
51. [51] Staffas, A., Karlsson, C., Persson, M., Palmqvist, L., Bergo, M.O., Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice. Leukemia 29:5 (2015), 1032–1040.
52. [52] Kong, G., Chang, Y.I., Damnernsawad, A., You, X., Du, J., Ranheim, E.A., Lee, W., Ryu, M.J., Zhou, Y., Xing, Y., Chang, Q., Burd, C.E., Zhang, J., Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis. Leukemia 30:7 (2016), 1542–1551.
53. [53] Xu, J., Haigis, K.M., Firestone, A.J., McNerney, M.E., Li, Q., Davis, E., Chen, S.C., Nakitandwe, J., Downing, J., Jacks, T., Le Beau, M.M., Shannon, K., Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discov. 3:9 (2013), 993–1001.
54. [54] Diaz, R., Lopez-Barcons, L., Ahn, D., Garcia-Espana, A., Yoon, A., Matthews, J., Mangues, R., Perez-Soler, R., Pellicer, A., Complex effects of Ras proto-oncogenes in tumorigenesis. Carcinogenesis 25:4 (2004), 535–539.
55. [55] Li, J., Zhang, Z., Dai, Z., Plass, C., Morrison, C., Wang, Y., Wiest, J.S., Anderson, M.W., You, M., LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer. Oncogene 22:8 (2003), 1243–1246.
56. [56] Qiu, W., Sahin, F., Iacobuzio-Donahue, C.A., Garcia-Carracedo, D., Wang, W.M., Kuo, C.Y., Chen, D., Arking, D.E., Lowy, A.M., Hruban, R.H., Remotti, H.E., Su, G.H., Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo. Oncotarget 2:11 (2011), 862–873.
57. [57] Wan, J., Li, H., Li, Y., Zhu, M.L., Zhao, P., Loss of heterozygosity of Kras2 gene on 12p 12–13 in Chinese colon carcinoma patients. World J. Gastroenterol. 12:7 (2006), 1033–1037.
58. [58] Soh, J., Okumura, N., Lockwood, W.W., Yamamoto, H., Shigematsu, H., Zhang, W., Chari, R., Shames, D.S., Tang, X., MacAulay, C., Varella-Garcia, M., Vooder, T., Wistuba, I.I., Lam, S., Brekken, R., Toyooka, S., Minna, J.D., Lam, W.L., Gazdar, A.F., Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One, 4(10), 2009, e7464.
59. [59] Logsdon, C.D., Lu, W., The significance of ras activity in pancreatic cancer initiation. Int. J. Biol. Sci. 12:3 (2016), 338–346.
60. [60] Jones, S., Zhang, X., Parsons, D.W., Lin, J.C., Leary, R.J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., Hong, S.M., Fu, B., Lin, M.T., Calhoun, E.S., Kamiyama, M., Walter, K., Nikolskaya, T., Nikolsky, Y., Hartigan, J., Smith, D.R., Hidalgo, M., Leach, S.D., Klein, A.P., Jaffee, E.M., Goggins, M., Maitra, A., Iacobuzio-Donahue, C., Eshleman, J.R., Kern, S.E., Hruban, R.H., Karchin, R., Papadopoulos, N., Parmigiani, G., Vogelstein, B., Velculescu, V.E., Kinzler, K.W., Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:5897 (2008), 1801–1806.
61. [61] Matallanas, D., Romano, D., Al-Mulla, F., O'Neill, E., Al-Ali, W., Crespo, P., Doyle, B., Nixon, C., Sansom, O., Drosten, M., Barbacid, M., Kolch, W., Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. Mol. Cell 44:6 (2011), 893–906.
62. [62] Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J., Lehar, J., Kryukov, G.V., Sonkin, D., Reddy, A., Liu, M., Murray, L., Berger, M.F., Monahan, J.E., Morais, P., Meltzer, J., Korejwa, A., Jane-Valbuena, J., Mapa, F.A., Thibault, J., Bric-Furlong, E., Raman, P., Shipway, A., Engels, I.H., Cheng, J., Yu, G.K., Yu, J., Aspesi, P. Jr., de Silva, M., Jagtap, K., Jones, M.D., Wang, L., Hatton, C., Palescandolo, E., Gupta, S., Mahan, S., Sougnez, C., Onofrio, R.C., Liefeld, T., MacConaill, L., Winckler, W., Reich, M., Li, N., Mesirov, J.P., Gabriel, S.B., Getz, G., Ardlie, K., Chan, V., Myer, V.E., Weber, B.L., Porter, J., Warmuth, M., Finan, P., Harris, J.L., Meyerson, M., Golub, T.R., Morrissey, M.P., Sellers, W.R., Schlegel, R., Garraway, L.A., The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:7391 (2012), 603–607.
63. [63] Cengel, K.A., Voong, K.R., Chandrasekaran, S., Maggiorella, L., Brunner, T.B., Stanbridge, E., Kao, G.D., McKenna, W.G., Bernhard, E.J., Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. Neoplasia 9:4 (2007), 341–348.
64. [64] Ikonomou, G., Kostourou, V., Shirasawa, S., Sasazuki, T., Samiotaki, M., Panayotou, G., Interplay between oncogenic K-Ras and wild-type H-Ras in Caco2 cell transformation. J. Proteom. 75:17 (2012), 5356–5369.
65. [65] Keller, J.W., Haigis, K.M., Franklin, J.L., Whitehead, R.H., Jacks, T., Coffey, R.J., Oncogenic K-RAS subverts the antiapoptotic role of N-RAS and alters modulation of the N-RAS:gelsolin complex. Oncogene 26:21 (2007), 3051–3059.
66. [66] Wolfman, J.C., Wolfman, A., Endogenous c-N-Ras provides a steady-state anti-apoptotic signal. J. Biol. Chem. 275:25 (2000), 19315–19323.
67. [67] Lim, K.H., Ancrile, B.B., Kashatus, D.F., Counter, C.M., Tumour maintenance is mediated by eNOS. Nature 452:7187 (2008), 646–649.
68. [68] Jeng, H.H., Taylor, L.J., Bar-Sagi, D., Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis. Nat. Commun., 3, 2012, 1168.
69. [69] Grabocka, E., Pylayeva-Gupta, Y., Jones, M.J., Lubkov, V., Yemanaberhan, E., Taylor, L., Jeng, H.H., Bar-Sagi, D., Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response. Cancer Cell 25:2 (2014), 243–256.
70. [70] Young, A., Lou, D., McCormick, F., Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov. 3:1 (2013), 112–123.
71. [71] Maruyama, C., Tomisawa, M., Wakana, S., Yamazaki, H., Kijima, H., Suemizu, H., Ohnishi, Y., Urano, K., Hioki, K., Usui, T., Nakamura, M., Tsuchida, T., Mitsumori, K., Nomura, T., Tamaoki, N., Ueyama, Y., Overexpression of human H-ras transgene is responsible for tumors induced by chemical carcinogens in mice. Oncol. Rep. 8:2 (2001), 233–237.
72. [72] Tsunematsu, S., Saito, H., Kagawa, T., Morizane, T., Hata, J., Nakamura, T., Ishii, H., Tsuchiya, M., Nomura, T., Katsuki, M., Hepatic tumors induced by carbon tetrachloride in transgenic mice carrying a human c-H-ras proto-oncogene without mutations. Int. J. Cancer 59:4 (1994), 554–559.
73. [73] Cancer Genome Atlas Research Network, The molecular taxonomy of primary prostate cancer. Cell 163:4 (2015), 1011–1025.
74. [74] Cancer Genome Atlas Research Network, Integrated genomic analyses of ovarian carcinoma. Nature 474:7353 (2011), 609–615.
75. [75] Min, J., Zaslavsky, A., Fedele, G., McLaughlin, S.K., Reczek, E.E., De Raedt, T., Guney, I., Strochlic, D.E., Macconaill, L.E., Beroukhim, R., Bronson, R.T., Ryeom, S., Hahn, W.C., Loda, M., Cichowski, K., An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat. Med. 16:3 (2010), 286–294.
76. [76] Barbieri, C.E., Rubin, M.A., Genomic rearrangements in prostate cancer. Curr. Opin. Urol. 25:1 (2015), 71–76.
77. [77] Wang, X.S., Shankar, S., Dhanasekaran, S.M., Ateeq, B., Sasaki, A.T., Jing, X., Robinson, D., Cao, Q., Prensner, J.R., Yocum, A.K., Wang, R., Fries, D.F., Han, B., Asangani, I.A., Cao, X., Li, Y., Omenn, G.S., Pflueger, D., Gopalan, A., Reuter, V.E., Kahoud, E.R., Cantley, L.C., Rubin, M.A., Palanisamy, N., Varambally, S., Chinnaiyan, A.M., Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer discovery 1:1 (2011), 35–43.
78. [78] Calvisi, D.F., Ladu, S., Conner, E.A., Seo, D., Hsieh, J.T., Factor, V.M., Thorgeirsson, S.S., Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J. Hepatol. 54:2 (2011), 311–319.
79. [79] Kolfschoten, I.G., van Leeuwen, B., Berns, K., Mullenders, J., Beijersbergen, R.L., Bernards, R., Voorhoeve, P.M., Agami, R., A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell 121:6 (2005), 849–858.
80. [80] Cancer Genome Atlas Network, Genomic Classification of Cutaneous MelanomaGenomic classification of cutaneous melanoma. Cell 161:7 (2015), 1681–1696.
81. [81] Verhaak, R.G., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., Miller, C.R., Ding, L., Golub, T., Mesirov, J.P., Alexe, G., Lawrence, M., O'Kelly, M., Tamayo, P., Weir, B.A., Gabriel, S., Winckler, W., Gupta, S., Jakkula, L., Feiler, H.S., Hodgson, J.G., James, C.D., Sarkaria, J.N., Brennan, C., Kahn, A., Spellman, P.T., Wilson, R.K., Speed, T.P., Gray, J.W., Meyerson, M., Getz, G., Perou, C.M., Hayes, D.N., Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:1 (2010), 98–110.
82. [82] Brennan, C.W., Verhaak, R.G., McKenna, A., Campos, B., Noushmehr, H., Salama, S.R., Zheng, S., Chakravarty, D., Sanborn, J.Z., Berman, S.H., Beroukhim, R., Bernard, B., Wu, C.J., Genovese, G., Shmulevich, I., Barnholtz-Sloan, J., Zou, L., Vegesna, R., Shukla, S.A., Ciriello, G., Yung, W.K., Zhang, W., Sougnez, C., Mikkelsen, T., Aldape, K., Bigner, D.D., Van Meir, E.G., Prados, M., Sloan, A., Black, K.L., Eschbacher, J., Finocchiaro, G., Friedman, W., Andrews, D.W., Guha, A., Iacocca, M., O'Neill, B.P., Foltz, G., Myers, J., Weisenberger, D.J., Penny, R., Kucherlapati, R., Perou, C.M., Hayes, D.N., Gibbs, R., Marra, M., Mills, G.B., Lander, E., Spellman, P., Wilson, R., Sander, C., Weinstein, J., Meyerson, M., Gabriel, S., Laird, P.W., Haussler, D., Getz, G., Chin, L., The somatic genomic landscape of glioblastoma. Cell 155:2 (2013), 462–477.
83. [83] Comprehensive molecular profiling of lung adenocarcinoma. Nature 511:7511 (2014), 543–550.
84. [84] Comprehensive genomic characterization of squamous cell lung cancers. Nature 489:7417 (2012), 519–525.
85. [85] Maertens, O., Johnson, B., Hollstein, P., Frederick, D.T., Cooper, Z.A., Messiaen, L., Bronson, R.T., McMahon, M., Granter, S., Flaherty, K., Wargo, J.A., Marais, R., Cichowski, K., Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 3:3 (2013), 338–349.
86. [86] Nissan, M.H., Pratilas, C.A., Jones, A.M., Ramirez, R., Won, H., Liu, C., Tiwari, S., Kong, L., Hanrahan, A.J., Yao, Z., Merghoub, T., Ribas, A., Chapman, P.B., Yaeger, R., Taylor, B.S., Schultz, N., Berger, M.F., Rosen, N., Solit, D.B., Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res. 74:8 (2014), 2340–2350.
87. [87] Whittaker, S.R., Theurillat, J.P., Van Allen, E., Wagle, N., Hsiao, J., Cowley, G.S., Schadendorf, D., Root, D.E., Garraway, L.A., A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 3:3 (2013), 350–362.
88. [88] Li, X., Dai, X., Wan, L., Inuzuka, H., Sun, L., North, B.J., Smurf1 regulation of DAB2IP controls cell proliferation and migration. Oncotarget, 2016, 10.18632/oncotarget.8424 In press, epub ahead of print.
89. [89] Kidger, A.M., Keyse, S.M., The regulation of oncogenic Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases (MKPs). Semin. Cell Dev. Biol. 50 (2016), 125–132.
90. [90] Zhang, Z., Kobayashi, S., Borczuk, A.C., Leidner, R.S., Laframboise, T., Levine, A.D., Halmos, B., Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis 31:4 (2010), 577–586.
91. [91] Rushworth, L.K., Kidger, A.M., Delavaine, L., Stewart, G., van Schelven, S., Davidson, J., Bryant, C.J., Caddye, E., East, P., Caunt, C.J., Keyse, S.M., Dual-specificity phosphatase 5 regulates nuclear ERK activity and suppresses skin cancer by inhibiting mutant Harvey-Ras (HRasQ61L)-driven SerpinB2 expression. Proc. Natl. Acad. Sci. U. S. A. 111:51 (2014), 18267–18272.
92. [92] Hanafusa, H., Torii, S., Yasunaga, T., Nishida, E., Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat. Cell Biol. 4:11 (2002), 850–858.
93. [93] Kim, H.J., Bar-Sagi, D., Modulation of signalling by Sprouty: a developing story. Nat. Rev. Mol. Cell Biol. 5:6 (2004), 441–450.
94. [94] Schutzman, J.L., Martin, G.R., Sprouty genes function in suppression of prostate tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 109:49 (2012), 20023–20028.
95. [95] Zhao, Z., Chen, C.C., Rillahan, C.D., Shen, R., Kitzing, T., McNerney, M.E., Diaz-Flores, E., Zuber, J., Shannon, K., Le Beau, M.M., Spector, M.S., Kogan, S.C., Lowe, S.W., Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis. Nat. Genet. 47:5 (2015), 539–543.
96. [96] Swanson, K.D., Winter, J.M., Reis, M., Bentires-Alj, M., Greulich, H., Grewal, R., Hruban, R.H., Yeo, C.J., Yassin, Y., Iartchouk, O., Montgomery, K., Whitman, S.P., Caligiuri, M.A., Loh, M.L., Gilliland, D.G., Look, A.T., Kucherlapati, R., Kern, S.E., Meyerson, M., Neel, B.G., SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients. Genes Chromosomes Cancer 47:3 (2008), 253–259.
97. [97] Ksionda, O., Limnander, A., Roose, J.P., RasGRP Ras guanine nucleotide exchange factors in cancer. Front. Biol. 8:5 (2013), 508–532.
98. [98] Oki, T., Kitaura, J., Watanabe-Okochi, N., Nishimura, K., Maehara, A., Uchida, T., Komeno, Y., Nakahara, F., Harada, Y., Sonoki, T., Harada, H., Kitamura, T., Aberrant expression of RasGRP1 cooperates with gain-of-function NOTCH1 mutations in T-cell leukemogenesis. Leukemia 26:5 (2012), 1038–1045.